A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

Study Overview

his randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.

Study Description

The purpose of this study is to demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument.

IRB Number: 1204008432 (RTOG0938)
Research Study Identifier: TX2472
Principal Investigator: Peter Johnstone, MD

Recruitment Status

Closed

Contact the research team to learn more about this study.

* Your Email

* First Name

Last Name

* Your Phone

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Recruitment Status

Closed

If you need assistance finding a study or if you have any questions, please email: ctsirro@iu.edu or call us at (317) 278-2176

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

Study Overview

Study Description

Recruitment Status

Contact the research team to learn more about this study.

Recruitment Status

Volunteer Registry